NICM
CYTK icon

Neo Ivy Capital Management’s Cytokinetics CYTK Stock Holding History

Neo Ivy Capital Management’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-15,944
Closed -$470K – 330
2023
Q3 		$470K Buy
+15,944
New +$531K 0.21% 173
2022
Q2 		– Sell
-4,992
Closed -$184K – 450
2022
Q1 		$184K Sell
4,992
-2,504
-33% -$89K 0.17% 218
2021
Q4 		$342K Buy
+7,496
New +$289K 0.49% 62

Other funds holding CYTK

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Neo Ivy Capital Management's CYTK Position: Q4 2023 in Review

Neo Ivy Capital Management sold out of Cytokinetics (CYTK) in Q4 2023, closing a stake of 15,944 shares — an estimated $470K sold.

Neo Ivy Capital Management first reported a position in CYTK in Q4 2021 and held it in 3 quarters. The position peaked at $470K in Q3 2023. 347 funds tracked by Wall St. Rank hold CYTK as of Q4 2023.

  • Neo Ivy Capital Management reported no remaining Cytokinetics position as of Q4 2023 after selling out during the quarter.
  • Neo Ivy Capital Management sold 15,944 Cytokinetics shares in Q4 2023, an estimated $470K.
  • Neo Ivy Capital Management first reported a position in Cytokinetics in Q4 2021 and held it in 3 quarters.
  • Neo Ivy Capital Management's Cytokinetics position peaked at $470K in Q3 2023.
  • 347 funds tracked by Wall St. Rank held Cytokinetics as of Q4 2023.

Based on Neo Ivy Capital Management's 13F filing for Q4 2023, filed 26 Feb 2024.